13 Feb 2016
For Clinicians
I was recently contacted by a physician with over 25 years of experience in designing and interpreting clinical trials who wanted to find out more about the role of mycobacteria in chronic inflammatory bowel disease. The following comments are quite interesting and should be reviewed by any physician remotely interested in advancing our understanding of the etiology, pathogenesis and treatment of Crohn’s disease. The conclusion is that there were major flaws in the design of the trial. Both sides can learn from this analysis.
Following the Selby Study analysis, an AMAT protocol is detailed for any clinician wishing to consider this therapy for Crohn’s disease.
Welcome to 
Many of you may have seen the viral Facebook post by Ste Walker, a young man who detailed his battle with Crohn’s disease and the public perception of this illness. Rather than give up, Ste has courageously started a new campaign to bring awareness to the plight of Crohn’s disease patients around the world. Read on to learn more about Ste’s fight against Crohn’s and his #SickButInvisible Campaign.
Dr. Tony Milici, GeneThera founder and CEO, announced his company’s expansion into the Crohn’s disease research field in a press release on January 25, 2016. GeneThera is dedicated to improving food safety by applying the latest molecular technologies to eradicate zoonotic diseases (those which cross from animals to the human population) such as Johne’s disease. Since it has long been thought that Johne’s disease, which is caused by the pathogen Mycobacterium avium spp paratuberculosis (MAP), has a zoonotic link to Crohn’s disease, GeneThera’s research could provide critically needed solutions.
Welcome to the first edition of The MAP Gap newsletter! The months since the August Chicago Symposium have flown by in a flurry of activity. We are happy to announce that TheCrohnsInfection.org will continue as a permanent site, not only to house the videos from the Chicago Symposium, but also to provide new information about the role of mycobacteria in Crohn’s disease.